These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33007647)

  • 1. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
    Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
    J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
    Hjorth M; Dandu N; Mellergård J
    PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
    CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
    Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
    Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
    Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
    Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Percentage of CD8
    Houston TW; Howlett-Prieto Q; Regenauer C; Testai FD; Yao F; Feng X; Reder AT
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36535763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
    Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
    Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis.
    Ghadiri M; Rezk A; Li R; Evans A; Giacomini PS; Barnett MH; Antel J; Bar-Or A
    Sci Rep; 2020 Jan; 10(1):356. PubMed ID: 31941953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
    Blumenfeld-Kan S; Staun-Ram E; Miller A
    Mult Scler Relat Disord; 2019 Sep; 34():29-37. PubMed ID: 31228713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Zinger A; Latham SL; Combes V; Byrne S; Barnett MH; Hawke S; Grau GE
    Mult Scler; 2016 Dec; 22(14):1883-1887. PubMed ID: 26931477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
    Henault D; Galleguillos L; Moore C; Johnson T; Bar-Or A; Antel J
    Neurology; 2013 Nov; 81(20):1768-72. PubMed ID: 24132373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.
    Kowarik MC; Astling D; Lepennetier G; Ritchie A; Hemmer B; Owens GP; Bennett JL
    Neurotherapeutics; 2021 Jan; 18(1):364-377. PubMed ID: 33258072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
    Muls N; Dang HA; Sindic CJ; van Pesch V
    PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    Paolicelli D; Manni A; D'Onghia M; Direnzo V; Iaffaldano P; Zoccolella S; Di Lecce V; Tortorella C; Specchia G; Trojano M
    J Neuroimmunol; 2017 Feb; 303():75-80. PubMed ID: 28043652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.
    Teniente-Serra A; Grau-López L; Mansilla MJ; Fernández-Sanmartín M; Ester Condins A; Ramo-Tello C; Martínez-Cáceres E
    Autoimmunity; 2016 Jun; 49(4):219-28. PubMed ID: 26829210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.